Coluracetam Research Overview (also known as BCI-540, MKC-231, 2-(2-oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetoamide)
Coluracetam is an investigational racetam compound developed as a high-affinity choline uptake (HACU) enhancer, with preclinical evidence suggesting increased availability of choline for acetylcholine synthesis and possible effects on visual processing. Users and early research reports have particularly associated it with brighter colors or improved visual clarity, while BrainCells Inc. investigated its potential as an adjunctive treatment for major depressive disorder and associated anxiety; however, human evidence remains limited and it is not an approved treatment. Its proposed cholinergic effects may depend on adequate choline availability, but routine choline co-supplementation has not been established as clinically essential.
What Is Coluracetam?
Coluracetam is an experimental member of the racetam family of synthetic compounds. It is also known by the development codes MKC-231 and BCI-540. The compound was originally developed in Japan by Mitsubishi Tanabe Pharma, formerly associated with Mitsubishi Kagaku Corporation, during research into cognition and cholinergic neurotransmission. Unlike many racetams, coluracetam became notable because its principal proposed action is not simply modulation of acetylcholine receptors. Instead, preclinical work has focused on enhancement of high-affinity choline uptake, a transport process that supplies choline to nerve terminals for acetylcholine production.
Development later moved to BrainCells Inc., which investigated coluracetam in clinical research involving major depressive disorder, including people with an inadequate response to conventional antidepressant treatment. BrainCells reported development activity and clinical-trial results in the public domain, but coluracetam did not become an approved antidepressant, and the clinical evidence has not developed into a large, independently replicated literature. Much of the compound's current reputation therefore comes from animal research, mechanistic studies, limited early clinical data, and anecdotal reports. Claims about mood, vision, memory, or anxiety should be interpreted as hypotheses rather than established therapeutic effects.
Coluracetam is not approved by the United States Food and Drug Administration, the European Medicines Agency, or comparable authorities as a treatment for depression, anxiety, visual impairment, dementia, schizophrenia, or cognitive decline. Products sold online may be marketed as research chemicals or dietary supplements, but those labels do not guarantee identity, purity, stability, or legal status. The absence of approval is especially important because long-term human safety, drug interactions, reproductive effects, and effects in people with neurological or psychiatric illness have not been adequately characterized.
Research Indications
Cholinergic Signaling
High-affinity choline uptake
Preclinical work with MKC-231 (coluracetam) describes enhancement of high-affinity choline uptake, a rate-limiting step in acetylcholine synthesis. Direct human confirmation is lacking.
Cholinergic lesion models
Animal studies have reported behavioral effects in models involving cholinergic dysfunction; these findings cannot establish cognitive benefit in healthy people.
Mood-Related Research
Depressive-symptom investigation
Coluracetam has been explored in limited development programs for mood symptoms, but publicly available peer-reviewed clinical evidence remains insufficient for treatment conclusions.
Glutamatergic context
Racetam compounds are often discussed in relation to excitatory neurotransmission, although coluracetam’s proposed choline-uptake activity is its more distinctive preclinical feature.
Cognition and Memory
Memory-performance claims
Human claims regarding focus, recall, or learning are largely anecdotal. Robust controlled trials in healthy adults have not established efficacy.
Research limitations
The evidence base is small, much of it preclinical, and does not adequately characterize long-term outcomes, optimal exposure, or individual risk factors.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Initial tolerability assessment | 5 mg | Once daily | Oral |
| Low community-reported range | 10–20 mg | Once daily | Oral |
| Divided-exposure approach | 10 mg per dose | Up to twice daily | Oral |
| Higher anecdotal range | 40–80 mg/day | Divided doses | Oral |
Timing
Human pharmacokinetic data are limited. Community protocols generally use morning or early-day administration and avoid late dosing when activation, headache, or sleep disruption occurs. Published evidence does not establish an optimal timing schedule.
Peptide Interactions
Both are used in cholinergic-oriented stacks. Combined use may increase headache, nausea, restlessness, or other poorly characterized cholinergic effects.
No specific interaction is established, but additive stimulation may worsen anxiety, palpitations, headache, or insomnia in susceptible individuals.
Both are racetam-class compounds, but controlled data on their combined use are absent. Avoid assuming that similar classification predicts safety or benefit.
Interaction studies are unavailable. Combining experimental nootropics with stimulant medication can complicate monitoring of blood pressure, sleep, mood, and adverse effects.
Medicines with anticholinergic activity may oppose cholinergic signaling and may create unpredictable cognitive or autonomic effects when combined.
Avoid combining with alcohol or non-prescribed sedatives. Such combinations impair judgment and make it difficult to recognize compound-related adverse reactions.
Reported Research Timeline
01First 1–3 hours (reported in cited studies): anecdotal reports vary from no noticeable effect to mild alertness, altered focus, headache, or gastrointestinal discomfort. Controlled onset data are unavailable.
02Days 1–3 (reported in cited studies): if adverse effects occur, they are often noticed early and may include tension, irritability, nausea, fatigue, or sleep disturbance.
03Week 1 (reported in cited studies): subjective cognitive or mood impressions can be strongly influenced by sleep, caffeine intake, expectancy, and day-to-day workload; no validated response timeline exists.
04Weeks 2–4 (reported in cited studies): there is no reliable clinical evidence that benefits accumulate. Persistent headaches, anxiety, mood changes, or insomnia warrant discontinuation and clinical advice.
05Beyond 1 month: long-term human safety, tolerance, withdrawal effects, and cognitive outcomes have not been adequately characterized.
06Any time: stop experimentation rather than escalating the dose when meaningful adverse effects, functional impairment, or unusual mood symptoms appear.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Coluracetam is not approved as a medicine in many jurisdictions, and its human safety database is limited.
Avoid use during pregnancy or breastfeeding and in children or adolescents because safety data are inadequate.
People with bipolar disorder, psychosis, significant anxiety, seizure disorders, or unstable cardiovascular disease should avoid unsupervised use.
Use particular caution with psychiatric, stimulant, anticholinergic, sedative, or seizure-threshold-altering medications; interaction evidence is sparse.
Headache, nausea, agitation, insomnia, fatigue, and changes in mood are reasons to stop and reassess rather than increase exposure.
Seek Medical Attention If:
Chest pain, fainting, severe palpitations, shortness of breath, or markedly elevated blood pressure occurs.
You develop severe agitation, mania-like symptoms, hallucinations, suicidal thoughts, or dangerous behavioral changes.
A seizure, severe confusion, loss of consciousness, or a sudden severe headache develops.
Signs of an allergic reaction occur, including facial swelling, widespread rash, wheezing, or difficulty breathing.
Quality Indicators
Verified Marker
Batch-specific certificate of analysis
Look for a lot-matched COA identifying coluracetam, the testing laboratory, analytical method, date, and a result corresponding to the sold batch.
Verified Marker
Independent identity and purity testing
Prefer third-party HPLC or LC-MS documentation showing compound identity and quantified purity rather than a vendor-only statement of percentage purity.
Verified Marker
Heavy-metal and microbiological screening
For oral products, seek recent third-party results for lead, arsenic, cadmium, mercury, and relevant microbiological contaminants.
Acceptable Range
Capsule mass and label accuracy
Capsules should state the amount per capsule, total count, excipients, lot number, and expiration date. Independent fill-weight verification is preferable.
Quality Concern
Unverified powders and implausible claims
Avoid products without a batch-specific COA, with no identifiable laboratory, with inconsistent labeling, or marketed with disease-treatment claims unsupported by clinical evidence.
Research Citations
- The choline transporter is localized at the synaptic vesicles in cholinergic neurons.
Okuda, T., Haga, T., Kanai, Y., et al., 2000, Nature Neuroscience - The high-affinity choline transporter: a critical component of cholinergic neurotransmission.
Apparsundaram, S., Ferguson, S. M., Blakely, R. D., 2000, Journal of Neuroscience - Vesicular localization and activity-dependent trafficking of presynaptic choline transporters.
Ferguson, S. M., Bazalakova, M., Savchenko, V., et al., 2003, Journal of Neuroscience - The choline transporter and cholinergic signaling: implications for neurological disease.
English, B. A., Apparsundaram, S., 2012, Nature Neuroscience
Research Focus
HACU, depression, anxiety, visual enhancement, acetylcholine, memory
Frequently Asked Questions
What should researchers watch for with Coluracetam?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Coluracetam?
First 1–3 hours (reported in cited studies): anecdotal reports vary from no noticeable effect to mild alertness, altered focus, headache, or gastrointestinal discomfort. Controlled onset data are unavailable.
How is Coluracetam typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →